search
Back to results

Predischarge Bundle to Minimize Negative Impact on Quality of Life of Nuisance Bleedings (BATMAN)

Primary Purpose

Myocardial Ischemia, Hemorrhage, Quality of Life

Status
Completed
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
good clinical practice
bundle group
Sponsored by
University Hospital of Ferrara
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Myocardial Ischemia

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • signed written informed consent
  • hospital admission for ischemic heart disease with clinical indication to coronary artery angiography
  • percutaneous coronary intervention and drug eluting stent implantation
  • indication to dual antiplatelet therapy for at least 6 months

Exclusion Criteria:

  • oral anticoagulant therapy
  • bleeding event in the 30 days before the enrolment
  • planned surgery

Sites / Locations

  • University Hospital of Ferrara

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Experimental

Arm Label

good clinical practice

bundle group

Arm Description

all patients will receive education from physician regarding management of dual antiplatelet therapy as part of the routine discharge process

patients assigned to the bundle group will receive visits and materials as described by the protocol (counseling)

Outcomes

Primary Outcome Measures

quality of life
quality of life assessment in each patient by EQ-5D questionnaire

Secondary Outcome Measures

emergency room admission
number of access to emergency room service for bleeding
general practitioner visit
number of access to general practitioner for bleeding
dyspnea occurrence
number of patients suffering dyspnoea stratified according P2Y12 inhibitors
bleeding academic research consortium (BARC) 2-3
occurrence of BARC 2-3 complications
bleeding academic research consortium (BARC) 1
occurrence of BARC 1 complications

Full Information

First Posted
September 17, 2015
Last Updated
May 1, 2018
Sponsor
University Hospital of Ferrara
search

1. Study Identification

Unique Protocol Identification Number
NCT02554006
Brief Title
Predischarge Bundle to Minimize Negative Impact on Quality of Life of Nuisance Bleedings
Acronym
BATMAN
Official Title
Predischarge Bundle for Patients in Dual Antiplatelet Therapy to Minimize the Negative Impact of Nuisance Bleedings on Quality of Life: a Randomized Controlled Trial.
Study Type
Interventional

2. Study Status

Record Verification Date
May 2018
Overall Recruitment Status
Completed
Study Start Date
September 2015 (Actual)
Primary Completion Date
March 2016 (Actual)
Study Completion Date
March 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University Hospital of Ferrara

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
A single-center, randomized trial of admitted patients with ischemic heart disease receiving percutaneous coronary intervention and stent implantation will be conducted at University Hospital of Ferrara. Patients will be randomized to either the control (standard care) or the bundle group in which patients will receive counseling regarding dual antiplatelet therapy management, advantages and side effects, screening for depression or anxiety, standardized education. The primary endpoint will be the difference in the quality of life as assessed by EQ-5D questionnaire.
Detailed Description
Recent studies suggest that bleeding complications have a strong influence on quality of life. During DAPT regimen bleeding complications occur from 5% to 15% of patients. Nuisance bleedings (BARC 1 bleeding) occur more frequently and show a strong influence on quality of life, depression, anxiety and compliance to the treatment. The aim of the study is to establish if a specific counseling programme might minimize the negative quality of life impact of nuisance bleedings. A computer-generated list will be used to randomize patients in a 1:1 ratio, stratified by age, sex, renal failure and P2Y12 inhibitor, to either the bundle or the control group. All patients randomized to the control group (standard of care) will receive education from physician regarding dual antiplatelet therapy (DAPT) as part of the routine discharge process. All patients randomized to the bundle group will receive: i) a 15-min visit by a member of the research team 24 h prior to the anticipated discharge day. During this visit, a core set of DAPT risks will be addressed. Advantages and side effects of DAPT will be described. The importance of compliance will be discussed. The correct management of side effects (especially BARC 1 bleedings) will be discussed. ii) a 15-min visit by a member of the research team with a family member living near/with the patient. Advantages and side effects of DAPT will be described. The importance of compliance will be discussed. The correct management of side effects (especially BARC 1 bleedings) will be discussed. iii) brochure describing advantages, side effects and management of dual antiplatelet therapy. Contemporaneously, the investigators of the study will contact directly by phone and/or mail the general practionnaire of the patient to describe and explain the same topics and the clinical problem of her patient. iv) availability of phone number to discuss potential side effects of DAPT. In addition, the study coordinator of the study will contact two times by month the patient by phone to assess DAPT compliance and potential BARC 1 bleedings.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Myocardial Ischemia, Hemorrhage, Quality of Life, Platelet Aggregation Inhibitors

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
448 (Actual)

8. Arms, Groups, and Interventions

Arm Title
good clinical practice
Arm Type
Other
Arm Description
all patients will receive education from physician regarding management of dual antiplatelet therapy as part of the routine discharge process
Arm Title
bundle group
Arm Type
Experimental
Arm Description
patients assigned to the bundle group will receive visits and materials as described by the protocol (counseling)
Intervention Type
Behavioral
Intervention Name(s)
good clinical practice
Other Intervention Name(s)
standard of care
Intervention Description
education from physician regarding dual antiplatelet therapy as part of the routine discharge process
Intervention Type
Behavioral
Intervention Name(s)
bundle group
Other Intervention Name(s)
counseling regarding dual antiplatelet therapy management
Intervention Description
visits and materials describing advantages and side effects of dual antiplatelet therapy and their management
Primary Outcome Measure Information:
Title
quality of life
Description
quality of life assessment in each patient by EQ-5D questionnaire
Time Frame
1 month
Secondary Outcome Measure Information:
Title
emergency room admission
Description
number of access to emergency room service for bleeding
Time Frame
1 month
Title
general practitioner visit
Description
number of access to general practitioner for bleeding
Time Frame
1 month
Title
dyspnea occurrence
Description
number of patients suffering dyspnoea stratified according P2Y12 inhibitors
Time Frame
1 month
Title
bleeding academic research consortium (BARC) 2-3
Description
occurrence of BARC 2-3 complications
Time Frame
1 month
Title
bleeding academic research consortium (BARC) 1
Description
occurrence of BARC 1 complications
Time Frame
1 month
Other Pre-specified Outcome Measures:
Title
ischemic adverse events
Description
cumulative incidence of the following ischemic adverse events: cardiac death, myocardial infarction, transient ischemic attack/stroke
Time Frame
1 year
Title
all-cause mortality
Description
occurrence of all-cause death
Time Frame
1 year
Title
BARC 1-3
Description
occurrence of BARC1-3 complications
Time Frame
1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: signed written informed consent hospital admission for ischemic heart disease with clinical indication to coronary artery angiography percutaneous coronary intervention and drug eluting stent implantation indication to dual antiplatelet therapy for at least 6 months Exclusion Criteria: oral anticoagulant therapy bleeding event in the 30 days before the enrolment planned surgery
Facility Information:
Facility Name
University Hospital of Ferrara
City
Cona
State/Province
Ferrara
ZIP/Postal Code
44124
Country
Italy

12. IPD Sharing Statement

Citations:
PubMed Identifier
28832589
Citation
Biscaglia S, Tonet E, Pavasini R, Serenelli M, Bugani G, Cimaglia P, Gallo F, Spitaleri G, Del Franco A, Aquila G, Vieceli Dalla Sega F, Tebaldi M, Tumscitz C, Ferrari R, Campo G. A counseling program on nuisance bleeding improves quality of life in patients on dual antiplatelet therapy: A randomized controlled trial. PLoS One. 2017 Aug 23;12(8):e0182124. doi: 10.1371/journal.pone.0182124. eCollection 2017.
Results Reference
result

Learn more about this trial

Predischarge Bundle to Minimize Negative Impact on Quality of Life of Nuisance Bleedings

We'll reach out to this number within 24 hrs